Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today
announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 11,600 shares of the Company’s common stock at an exercise
price per share of $21.64, which was the closing price on June 8, 2023, and restricted stock units to acquire a total of 5,800 shares of the Company’s common stock. The equity awards were granted
pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule
303A.08.
About Arcus Biosciences